Patients with PAH who achieve recovery to WHO-FC I or II without use of intravenous epoprostenol have similar survival to those who reach the same WHO-FC with use of intravenous epoprostenol. BMC Research Notes, June 2014; 7: 359. (Also see: Pulmonary Hypertension Prognosis)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.